Candel Therapeutics, Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, Candel Therapeutics is in Stage 3, the topping phase, now in its first week (since Oct 21, 2026). It closed at $8.38, 39.1% below its 52-week high and above its 200-day average, which is rising.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. More about the company

$8.38

+0.12% today

$641M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is CADL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S2 23w

S4 14w

S2 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 18w → S1 6w → S2 23w → S3 9w → S2 7w → S3 2w → S4 4w → S1 5w → S2 8w → S3 6w → S4 9w → S1 11w → S4 14w → S1 4w → S2 5w → S3 2w → S4 6w → S1 1w → S2 24w → S3 1w current

Total tracked: 165 weeks across 20 stage runs.

CADL among Biotechnology87th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…87	CADLCandel Therapeutics, Inc.	Stage 3 · wk 1	87	−25.8%

vs 52W High

-39.1%

$4.42 lo$13.75 hi

39.1% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

2.1%

200 DMA: $8.21 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.62x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-25.8%

-12.3%

+19.0%

YTD

+54.0%

+52.6%

Scan Membership

Breakout Watch

Latest: 2025-01-31

3 appearances in last 60 days. First seen: 2024-02-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 1 · Vol 0.62x

2026-10-21S32→3

Wk 1 · Vol 0.92x

2026-10-20S2

Wk 23 · Vol 0.94x

2026-10-19S2

Wk 23 · Vol 1.08x

2026-10-16S2

Wk 23 · Vol 1.28x

2026-10-15S2

Wk 23 · Vol 0.84x

2026-10-14S2

Wk 22 · Vol 0.84x

2026-10-13S2

Wk 22 · Vol 0.96x

2026-10-12S2

Wk 22 · Vol 0.63x

2026-10-09S2

Wk 22 · Vol 0.61x

2026-10-08S2

Wk 22 · Vol 0.74x

2026-10-07S2

Wk 21 · Vol 0.59x

Moving averages & range

50 DMA

$11.16

200 DMA

$8.21

52W High

$13.75

52W Low

$4.42

5D Low

$8.19

Resistance levels (recent highs)

20d High

$11.19

60d High

$13.75

120d High

$13.75

250d High

$13.75

Next resistance

+33.5%

to 20d High

ROE

-81.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 5.1

Candel Therapeutics: quick answers

What stage is Candel Therapeutics in?

As of Oct 22, 2026, Candel Therapeutics (CADL) is in Stage 3, the topping phase. It entered Stage 3 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Candel Therapeutics in an uptrend?

Its uptrend has stalled. Candel Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 2.1% above its 200-day average, which is rising.

How far is Candel Therapeutics from its 52-week high?

Candel Therapeutics closed at $8.38 on Oct 22, 2026, 39.1% below its 52-week high of $13.75. Its 52-week low is $4.42.

How has Candel Therapeutics performed over the past year?

As of Oct 22, 2026, Candel Therapeutics is up 52.6% over the past year and up 54.0% so far in 2026.

Which sector and industry is Candel Therapeutics in?

Candel Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.